US FDA Generic Drug Approvals, Other Actions Declined As Approval Times Climbed In FY 2024

 
• By Derrick Gingery
  
The FY 2024 generic drugs activity data likely will inform user fee reauthorization negotiations, which will begin in 2025. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics